Clinical Trial Update: Bisphosphonate Treatment of Osteogenesis Imperfecta [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating bisphosphonate therapy for osteogenesis imperfecta has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteogenesis Imperfecta

Drugs mentioned

• Bisphosphonates (bisphosphonate)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Osteogenesis Imperfecta | Phase 2 | Status: COMPLETED